US Biotech Insider Transactions Diverge: ImmunityBio (IBRX.US) Sees Largest Cashout, Sellas (SLS.US) Director Buys In Before 5x Surge

According to Zhitong Finance APP, in the biotech sector, while drug development progress is certainly the core variable for stock prices, the buying and selling trends of company insiders are also an important factor for assessing a company’s prospects. From this perspective, insider actions at Capricor (CAPR.US), ImmunityBio (IBRX.US), Sellas (SLS.US), and Iovance (IOVA.US) present vastly different pictures: some have cashed out at high levels, some have bucked the trend to buy in, and some remain on the sidelines.